Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Pharmagreen Issues Statement On Potential Stock Promotion

12/17/2019 | 09:01am EST

CARSON CITY, NV, Dec. 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), a company specializing in the development of tissue cultured starter plantlets for the hemp industry, today announced that on December 16, 2019 it was made aware OTC Markets Group added a Megaphone next to the Company’s trading symbol, representing potential promotional activities surrounding the Company’s common stock.

Promotional activities generally may involve promotional newsletters, styled as “paid announcements”.  The paid announcements generally encourage investors to put the Company’s common stock on their watch list. These apparent third-party promotional activities usually coincide with higher than average trading volume and fluctuations in the Company’s stock price.

Notwithstanding that a Form 8-K filed with the Securities and Exchange Commission on September 11, 2019 announcing that Pharmagreen entered into a consulting agreement with Emerging Markets Consulting, LLC (“EMC”) pursuant to which Pharmagreen engaged EMC for a term of 18 months to provide corporate communications, marketing, and related public relations services, and Private Equity Markets, LLC which is engaged on a month to month basis to provide coverage through their social media IR program were not promotional activities.

Apart from the OTC Markets Group notification, the Company was unaware of any promotional activity, and had not been previously notified by OTC Markets Group, and could not locate any such promotional activity online.  Further, the Company is unaware of the full nature of any such promotional activity, the extent of its public dissemination, or the responsible parties.

None of the Company, its officers, directors, employees, consultants, and, to the Company’s knowledge, its controlling or affiliated stockholders (i.e., stockholders who own 10% or more of the Company’s issued and outstanding common stock) has, directly or indirectly, authorized or been involved in any way (including any payments to one or more third-parties) with the authorization, creation, or distribution of any promotional materials, including those noted above.  Further, none of the Company, its officers, directors, employees, consultants, who sold or purchased shares of common stock of the Company within the last 30 days, are aware of any such promotional activities. 

The Company routinely responds to inquiries from stockholders, potential investors, and investment analysts, and generates its own press releases. As such, the Company urges persons interested in the Company, whether or not they are currently stockholders of the Company, to review its filings at sec.gov and visit the Company’s website and only to rely on information about the Company and about the industry sectors in which it operates that the Company has released. The Company is pleased to address any verification of public material through this designated email address: info@pharmagreen.ca.

The Company is not affiliated in any way with the authors of any promotional “newsletters,” paid announcements, or other such materials.  The Company routinely issues press releases in the regular course of its business and includes disclosure of its business activities in its filings with the Securities and Exchange Commission.  Investors are strongly encouraged to rely only on information provided directly by the Company.

About Pharmagreen Biotech, Inc. and WFS Pharmagreen Inc.

WFS Pharmagreen Inc. is a wholly owned Canadian based subsidiary of Pharmagreen Biotech, Inc., a publicly traded (OTC PINKS: PHBI) company.  WFS Pharmagreen Inc. is a tissue culture company that produces hemp plantlets through a proprietary tissue culture process.  Pharmagreen’s mission is to advance the technology of tissue culture science and to provide the highest quality 100% germ free, disease free and all genetically the same hemp plantlets with high Cannabinoids content and with less than 0.3% THC and other flora while offering full spectrum DNA testing for plant identification, live genetics preservation using low temperature storage for various plant species.   For further information on the company progress on the construction of a 63,000 square foot “Tissue Culture Biotech Complex” please visit www.pharmagreen.ca

Safe Harbor Statement

This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. In particular, factors that could cause actual results to differ materially from those in forward looking statements include: our inability to obtain additional financing on acceptable terms; risk that our products and services will not gain widespread market acceptance; inability to compete with others who provide comparable products; the failure of our technology; the infringement of our technology with proprietary rights of third parties; inability to respond to consumer demands; inability to replace significant customers; seasonal nature of our business. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements. When used in this document, the words "believe," "expect," "anticipate," "estimate," "project," "plan," "should," "intend," "may," "will," "would," "potential," and similar expressions may be used to identify forward-looking statements. 

The OTC Markets or any other securities regulatory authority has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release that has been prepared by management. 

Contact Information:


Tel: (702) 803 9404

Email: info@pharmagreen.ca

Primary Logo

© GlobeNewswire 2019
12/02PHBI - Pharmagreen Taps Revenue Potential of Proprietary Cannabis Tissue Culture Techno..
12/02Pharmagreen Taps Revenue Potential of Proprietary Cannabis Tissue Culture Technology As..
11/11Pharmagreen Prepares for Entry Into the Multi-Billion Dollar California Cannabis Indust..
11/04Pharmagreen Submits Its Application for Uplisting to the OTCQB Venture Market
09/29PHARMAGREEN BIOTECH : Provides Update on Funding and Acquisition Progress
08/24PHARMAGREEN BIOTECH : Production and Broadcast Agreement (Form 8-K)
08/24PHARMAGREEN BIOTECH INC. : Entry into a Material Definitive Agreement, Financial Statement..
08/18PHARMAGREEN BIOTECH : Management's Discussion and Analysis of Financial Condition and Resu..
08/18Pharmagreen Biotech Inc. Reports Earnings Results for the Third Quarter Ended June 30, ..
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 -2,44 M - -
Net Debt 2020 0,70 M - -
P/E ratio 2020 -2,69x
Yield 2020 -
Capitalization 8,44 M 8,44 M -
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees -
Free-Float 86,2%
Duration : Period :
Pharmagreen Biotech Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Peter Wojcik President, CEO, Secretary, Treasurer & Director
Terry Kwan Director, Chief Financial & Accounting Officer
Fawzia Afreen Chief Operations Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298